Low Incidence of BK Virus Nephropathy After Simultaneous Kidney Pancreas Transplantation

@article{Gupta2006LowIO,
  title={Low Incidence of BK Virus Nephropathy After Simultaneous Kidney Pancreas Transplantation},
  author={Gaurav Gupta and Ron Shapiro and Ngoc L. Thai and Parmjeet S. Randhawa and Abhay N Vats},
  journal={Transplantation},
  year={2006},
  volume={82},
  pages={382-388}
}
Background. BK virus renal allograft nephropathy (BKVAN) in the setting of simultaneous kidney-pancreas transplantation (SKPT) has been inadequately studied and reported. We analyzed our data on the incidence of BKVAN and its outcome in SKPT recipients at University of Pittsburgh Medical Center (UPMC) and affiliated centers and report significant differences compared to previous studies. Methods. This study used retrospective review and case studies. Results. A review of 243 consecutive SKPT… Expand
Development of BK Nephropathy in Recipients of Simultaneous Pancreas-Kidney Transplantation
TLDR
A single center, retrospective review was conducted of 205 SPK transplants performed from January 1, 2000 to April 30, 2006, and found there was no difference in the cumulative rate of BKVN between patients who received alemtuzumab or rabbit antilymphocyte globulin. Expand
Outcome in Pancreas Grafts After BK Virus Viremia in Simultaneous Pancreas-Kidney Transplants: A Single-Center Case Report
TLDR
BKVN treatment consists primarily of reducing IS, and attempts to decrease IS bring clinicians face to face with the delicate task of preventing kidney graft failure and avoiding rejection of the pancreatic allograft. Expand
BK nephropathy in the native kidneys of patients with organ transplants: Clinical spectrum of BK infection
TLDR
In patients with solid organ transplants, bone marrow transplants and in patients with other clinical entities associated with immunosuppression, BK nephropathy of the native kidneys has being increasingly recognized as a cause of chronic kidney disease. Expand
Renal Failure Five Years After Lung Transplantation Due to Polyomavirus BK‐Associated Nephropathy
TLDR
A 67‐year‐old female presenting with hypertension and progressive kidney failure due to PyVAN 60 months after lung transplantation is described and mTOR inhibitors versus cidofovir and leflunomide as potentialPyVAN rescue therapy is discussed. Expand
Kidney retransplantation following graft loss to polyoma virus‐associated nephropathy: an effective treatment option in simultaneous pancreas and kidney transplant recipients
TLDR
ReKT represents an effective treatment option in SPK patients with kidney failure on account of PVAN and use of interventions designed to reduce active viral replication, including pre‐emptive nephrectomy of the failed graft, should be considered before reKT. Expand
Immunosuppression in Simultaneous Pancreas-Kidney Transplantation
TLDR
Induction therapy with either alemtuzumab or rabbit antithymocyte globulin in combination with a calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF) or sirolimus appears to be safe and effective in the setting of rapid steroid withdrawal (RSW), with excellent graft survival and low rejection rates. Expand
Cost-Effectiveness of Cidofovir Treatment of Polyomavirus Nephropathy in Kidney Transplant Recipients
TLDR
Cidofovir treatment and immunosuppression reduction for BKVAN seem to be cost saving and improves health outcomes, but because of weak clinical data, particularly around comparative effectiveness, there is still moderate uncertainty in the incremental cost effectiveness. Expand
BKV-infection in kidney graft dysfunction.
  • J. Montagner, T. Michelon, +6 authors C. Alexandre
  • Medicine, Biology
  • The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • 2010
TLDR
DC, BKV-viruria and -viremia are found under late kidney graft dysfunction and could only be predicted by intense viruria, which is considered under the context of BKN confirmation. Expand
Epidemiology of BK Virus in Renal Allograft Recipients: Independent Risk Factors for BK Virus Replication
TLDR
Steroid maintenance therapy and induction with antithymocyte globulin are independent risk factors for BKV replication in renal allograft recipients treated with tacrolimus and mycophenolate mofetil. Expand
Risks and Epidemiology of Infections After Pancreas or Kidney–Pancreas Transplantation
TLDR
Pancreas transplantation offers the most reliable way to achieve euglycemia for insulin-dependent patients thanks to refinements in surgical technique, immunosuppression, donor and recipient selection, and the incidence of complications remains the highest of all performed solid organ transplants. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 33 REFERENCES
BKV in Simultaneous Pancreas‐Kidney Transplant Recipients: A Leading Cause of Renal Graft Loss in First 2 Years Post‐Transplant
  • G. Lipshutz, H. Mahanty, +5 authors C. Freise
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2005
TLDR
PVAN was the leading cause of renal loss in SPK patients in the first 2 years after transplantation and is a serious concern for SPK recipients, and the pancreas is spared from evidence of infection. Expand
Polyomavirus-associated nephropathy in simultaneous kidney-pancreas transplant recipients: a single-center experience.
TLDR
The clinical course of SPK patients who developed documented polyoma infection in the transplanted kidney is outlined, and a better treatment strategy is needed to prevent renal graft loss when polyoma is diagnosed. Expand
Clinical course of polyoma virus nephropathy in 67 renal transplant patients.
TLDR
It is concluded that PVN is a serious hazard for renal transplant recipients and contributes directly to graft loss and antiviral drugs are needed, as the reduction of immunosuppression alone may not significantly improve graft function in patients with already established PVN. Expand
Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients.
TLDR
BKV nephropathy in renal-transplant recipients represents a secondary infection associated with rejection and its treatment in most cases and could be monitored by measuring the viral load in plasma. Expand
Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss.
TLDR
Recurrent rejection episodes and high dose immunosuppressive therapy, including tacrolimus, are risk factors for manifest PV kidney graft infection, which has an ominous prognosis. Expand
Polyomavirus-Associated Nephropathy in Renal Transplantation: Interdisciplinary Analyses and Recommendations
TLDR
It is recommended that all renal transplant recipients should be screened for BKV replication in the urine every three months during the first two years posttransplant; and if PVAN and concurrent acute rejection is diagnosed, antirejection treatment should be considered, coupled with subsequently reducing immunosuppression. Expand
BK polyoma virus nephropathy in kidney transplant recipient: the role of new immunosuppressive agents.
TLDR
The experience with 7 patients with BKV nephropathy is described with specific attention to possible risk factors and introduction of new and more aggressive immunosuppressive protocols may explain the emergence of this new infectious complication. Expand
Treatment of Refractory BK Virus‐Associated Nephropathy With Cidofovir
  • Pradeep V. Kadambi, M. Josephson, +4 authors A. Limaye
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2003
TLDR
Preliminary data suggest that low‐dose cidofovir may be tolerated, even among renal transplant recipients with significant renal dysfunction due to BKVN, and Prospective, controlled trials are warranted to further define the optimal dose, toxicity and potential role of cid ofovir in renal transplant recipient with BK virus nephropathy. Expand
Polyomavirus nephropathy in native kidneys of non-renal transplant recipients.
  • A. Limaye, Kelly D. Smith, +4 authors M. Boeckh
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2005
TLDR
The results extend the populations in which PVN has been documented in native kidneys to include heart and stem cell transplant recipients, and suggest that cidofovir has activity against BKV in vivo. Expand
Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy.
TLDR
Surveillance allograft biopsy provides an important means for earlier detection of PVAN and permits timely alterations to immunosuppression, and is associated with a lesser degree of interstitial fibrosis at diagnosis and lower baseline and subsequent serum creatinine. Expand
...
1
2
3
4
...